Proactive Investors - Run By Investors For Investors

AstraZeneca reports pancreatic cancer trial success for Lynparza

Lynparza though showed significantly increased rates of survival in the phase III POLO trial
Parp-1 inhibitors stop cancer cells repairing themselves

AstraZeneca PLC (LON:AZN) has claimed the first positive result by a Parp-1 inhibitor as a treatment for one type of pancreatic cancer.

Pancreatic cancer is one of the hardest to treat as it is very hard to spot and patients often only become aware of the disease when it is too late for effective treatment.

READ: AstraZeneca rises as Brilinta medicine meets goal in Phase III clinical trial

Lynparza though showed significantly increased rates of survival in the phase III POLO trial.

José Baselga, Astra's head of oncology research, said: "This is the first positive Phase III trial of any PARP inhibitor in germline BRCA-mutated metastatic pancreatic cancer, a devastating disease with critical unmet need.

Parp-1 inhibitors stop cancer cells repairing themselves while BRCA-1 and -2 genes are the body's tumour suppressants and mutations of these can significantly increase the risk of occurrence.

"The results of POLO provide further evidence of the clinical benefit of Lynparza across a variety of BRCA-mutated tumour types. We will discuss these results with global health authorities as soon as possible," added Baselga.

Lynparza is being developed jointly by Astra and US group Merck.

"The clinically-meaningful results of this trial potentially support the value of testing for germline BRCA mutations in patients with metastatic pancreatic cancer," said Roy Baynes, Merck's head of global clinical development.

View full AZN profile View Profile

AstraZeneca Timeline

Related Articles

Callitas CEO James Thompson
July 20 2018
CannaStrips will generate near-term revenue, while the company’s blue-sky pharmaceutical assets and orphan drug are solid, long-term plays
September 18 2018
The company is utilising technology and big data to tackle the growing healthcare crisis and personalise treatment options for preventative care.
A woman with severe depression
April 25 2019
The New York clinical-stage biopharmaceutical company has several drugs in the pipeline capable of generating hefty revenue

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use